These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 29735704)

  • 1. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.
    Nguyen M; Wong YC; Ysselstein D; Severino A; Krainc D
    Trends Neurosci; 2019 Feb; 42(2):140-149. PubMed ID: 30509690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila.
    Inoshita T; Arano T; Hosaka Y; Meng H; Umezaki Y; Kosugi S; Morimoto T; Koike M; Chang HY; Imai Y; Hattori N
    Hum Mol Genet; 2017 Aug; 26(15):2933-2948. PubMed ID: 28482024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson's disease.
    Vidyadhara DJ; Somayaji M; Wade N; Yücel B; Zhao H; Shashaank N; Ribaudo J; Gupta J; Lam TT; Sames D; Greene LE; Sulzer DL; Chandra SS
    Cell Rep; 2023 Mar; 42(3):112231. PubMed ID: 36920906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
    Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
    Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2.
    Connor-Robson N; Booth H; Martin JG; Gao B; Li K; Doig N; Vowles J; Browne C; Klinger L; Juhasz P; Klein C; Cowley SA; Bolam P; Hirst W; Wade-Martins R
    Neurobiol Dis; 2019 Jul; 127():512-526. PubMed ID: 30954703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
    Heaton GR; Landeck N; Mamais A; Nalls MA; Nixon-Abell J; Kumaran R; Beilina A; Pellegrini L; Li Y; ; Harvey K; Cookson MR
    Neurobiol Dis; 2020 Jul; 141():104948. PubMed ID: 32434048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
    Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
    Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration.
    Liu Q; Bautista-Gomez J; Higgins DA; Yu J; Xiong Y
    Sci Signal; 2021 Jul; 14(693):. PubMed ID: 34315807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson's disease.
    Khan SS; Jaimon E; Lin YE; Nikoloff J; Tonelli F; Alessi DR; Pfeffer SR
    Proc Natl Acad Sci U S A; 2024 Aug; 121(32):e2402206121. PubMed ID: 39088390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 at the pre-synaptic site: A 16-years perspective.
    Pischedda F; Piccoli G
    J Neurochem; 2021 Apr; 157(2):297-311. PubMed ID: 33206398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
    Bono F; Mutti V; Devoto P; Bolognin S; Schwamborn JC; Missale C; Fiorentini C
    Neurobiol Aging; 2021 Mar; 99():65-78. PubMed ID: 33422895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.
    Xiong Y; Neifert S; Karuppagounder SS; Liu Q; Stankowski JN; Lee BD; Ko HS; Lee Y; Grima JC; Mao X; Jiang H; Kang SU; Swing DA; Iacovitti L; Tessarollo L; Dawson TM; Dawson VL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1635-1640. PubMed ID: 29386392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.